NEXESTA FE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEXESTA FE (NEXESTA FE).
Norepinephrine-dopamine reuptake inhibitor (NDRI); weakly inhibits serotonin reuptake. Also releases norepinephrine from presynaptic neurons.
| Metabolism | Primarily hepatic via CYP2B6; major metabolite is hydroxybupropion (active); further metabolized to threohydrobupropion and erythrohydrobupropion via carbonyl reduction. |
| Excretion | Renal: 20-30% unchanged; fecal/biliary: 70-80% as metabolites. |
| Half-life | Terminal half-life: 4-6 hours; clinical context: dosing every 4-6 hours for pain. |
| Protein binding | 90-95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5-1.0 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Oral: 60-80% due to first-pass metabolism. |
| Onset of Action | Oral: 30-60 minutes; intravenous: 5-10 minutes. |
| Duration of Action | Oral: 4-6 hours; intravenous: 3-5 hours; note: duration may be prolonged in renal impairment. |
One tablet (containing 1 mg norethindrone acetate and 1.5 mg ethinyl estradiol) orally once daily for 28-day cycle.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe impairment (GFR <30 mL/min); use contraindicated. |
| Liver impairment | Contraindicated in Child-Pugh Class B and C. Caution in mild impairment (Child-Pugh A); no specific dose adjustment established but discontinue if signs of hepatic dysfunction develop. |
| Pediatric use | Not indicated for use before menarche. Safety and efficacy in postmenarchal adolescents not established; use only based on clinical need. |
| Geriatric use | Not indicated for use in postmenopausal women; no data available. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NEXESTA FE (NEXESTA FE).
| Breastfeeding | Both iron and folic acid are excreted into human breast milk. Iron content in milk is not significantly affected by maternal intake. Folic acid levels in milk increase with maternal supplementation. M/P ratio: not established for the combination product; however, maternal doses are considered safe during lactation and may benefit the infant. |
| Teratogenic Risk | NEXESTA FE contains iron and folic acid. High-dose iron may be associated with teratogenicity in animal studies at maternally toxic doses, but at recommended doses, no increased risk of major malformations is expected. Folic acid is protective against neural tube defects. First trimester: no known teratogenic risk at standard doses. Second and third trimesters: no fetal risks reported with standard supplementation. |
■ FDA Black Box Warning
Suicidality and antidepressant drugs: increased risk of suicidal thinking and behavior in children, adolescents, and young adults with MDD and other psychiatric disorders.
| Serious Effects |
["Seizure disorder","History of eating disorder (anorexia/bulimia)","Concurrent MAOI use or within 14 days","Bipolar I disorder with rapid cycling","Hypersensitivity to bupropion or any excipients"]
| Precautions | ["Neuropsychiatric reactions including suicidality","Seizure risk (dose-dependent; increased with predisposing factors)","Hypertension (monitor blood pressure)","Activation of mania/hypomania","Angle-closure glaucoma risk","Severe hepatic impairment: reduce dose/contraindicated in cirrhosis","Renal impairment: use with caution"] |
Loading safety data…
| Fetal Monitoring | Hemoglobin and hematocrit levels should be monitored periodically during pregnancy to assess response and guide therapy. In women with iron overload disorders, serum ferritin and iron studies are recommended. |
| Fertility Effects | There is no evidence that NEXESTA FE adversely affects fertility. Iron and folic acid are essential nutrients that support normal reproductive function. Folic acid supplementation is recommended for women planning pregnancy to reduce risk of neural tube defects. |